Should High-Risk Smoldering Myeloma Be Treated? Exploring CAR-T & Combination Therapy Options
Should high-risk smoldering multiple myeloma (HR-SMM) be treated, and if so, how? In this webinar, Dr. Omar Nadeem will discuss the latest research on early treatment strategies, including CAR-T and combination therapy. Learn who may benefit from early treatment, the potential risks and benefits, and what these advances mean for the future of myeloma care. Whether you're a patient, caregiver, or advocate, this webinar will provide valuable insights to help you make informed decisions. Register now to join the discussion!
Cynthia introduces the agenda of the event and featured speaker Dr. Omar Nadeem
Dr. Nadeem discusses the latest research on early treatment strategies, including CAR-T and combination therapy
Type your questions in the chat and we will answer them!
Cynthia Cahoon, RN
Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.
Omar Nadeem, MD
Dr. Omar Nadeem completed his internal medicine residency training at Dartmouth-Hitchcock Medical Center and his hematology/oncology fellowship at the Warren Alpert Medical School of Brown University. He joined the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in 2018. He is an assistant professor at Harvard Medical School and serves as the Clinical Director of Myeloma Cellular Therapies Program and Medical Director of Center for Early Detection and Interception of Blood Cancers the Dana-Farber Cancer Institute. His clinical and research interests include studying the role of immunotherapy and cellular therapies in multiple myeloma, with particular focus on CAR T therapy. He serves as a principal investigator of several clinical trials in smoldering multiple myeloma, newly diagnosed disease and relapsed and refractory multiple myeloma.